The Mir-182-5P/FGF21/Acetylcholine Axis Mediates the Crosstalk Between Adipocytes and Macrophages to Promote Beige Fat Thermogenesis

Total Page:16

File Type:pdf, Size:1020Kb

The Mir-182-5P/FGF21/Acetylcholine Axis Mediates the Crosstalk Between Adipocytes and Macrophages to Promote Beige Fat Thermogenesis The miR-182-5p/FGF21/acetylcholine axis mediates the crosstalk between adipocytes and macrophages to promote beige fat thermogenesis Wen Meng, … , Feng Liu, Juli Bai JCI Insight. 2021. https://doi.org/10.1172/jci.insight.150249. Research In-Press Preview Endocrinology Metabolism Graphical abstract Find the latest version: https://jci.me/150249/pdf The miR-182-5p/FGF21/acetylcholine axis mediates the crosstalk between adipocytes and macrophages to promote beige fat thermogenesis Wen Meng 1,#, Ting Xiao1,#, Xiuci Liang1, Jie Wen1,2 , Xinyi Peng1,2, Jing Wang1, Yi Zou3, Jiahao Liu1, Christie Bialowas4, Hairong Luo1, Yacheng Zhang1,5, Bilian Liu1, Jingjing Zhang1, Fang Hu1, Meilian Liu1,6, Lily Q. Dong7, Zhiguang Zhou1, Feng Liu1,2,* and Juli Bai1,2,* 1National Clinical Research Center for Metabolic Diseases, Metabolic Syndrome Research Center, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China. Departments of 2Pharmacology, 3Greehey Children’s Cancer Research Institute, and 7Cell Systems & Anatomy, University of Texas Health at San Antonio, San Antonio, Texas, USA 4Division of Plastic Surgery, Department of Surgery, Albany Medical Center, Albany, NY 12208-3403 5Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang, China 6Department of Biochemistry and Molecular Biology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA *Corresponding author: E-mail: [email protected] or [email protected] Mailing address: Department of Pharmacology, University of Texas Health San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas, 78229. Juli Bai Phone: 210-567-4526; Email: [email protected]; Feng Liu: 210-567-3097; Email: [email protected] #These authors contribute equally to the work Running title: miR-182-mediated immune regulation of beige fat development Word Count: 7314 words. Number of Figures: 6 Number of Tables: 0 1 1 Abstract 2 A dynamically regulated microenvironment, which is mediated by crosstalks between adipocytes 3 and neighboring cells, is critical for adipose tissue homeostasis and function. However, information on 4 key molecules and/or signaling pathways regulating the crosstalks remains limited. In this study, we 5 identify adipocyte miR-182-5p as a crucial anti-obesity molecule that stimulates beige fat thermogenesis 6 by promoting the crosstalk between adipocytes and macrophages. miR-182-5p is highly enriched in 7 thermogenic adipocytes and its expression is markedly stimulated by cold exposure in mice. In contrast, 8 miR-182-5p expression is significantly reduced in adipose tissues of obese humans and mice. Knockout 9 of miR-185-5p decreased cold-induced beige fat thermogenesis whereas overexpression of miR-185-5p 10 increased beiging and thermogenesis in mice. Mechanistically, miR-182-5p promotes FGF21 expression 11 and secretion in adipocytes by suppressing Nr1d1 at 5'UTR, which in turn stimulates acetylcholine 12 synthesis and release in macrophages. Increased acetylcholine expression activates the nicotine 13 acetylcholine receptor in adipocytes, which stimulates PKA signaling and consequent thermogenic gene 14 expression. Our study reveals a key role of the miR-182-5p/FGF21/acetylcholine/acetylcholine receptor 15 axis that mediates the crosstalk between adipocytes and macrophages to promote beige fat 16 thermogenesis. Activation of the miR-182-5p-induced signaling pathway in adipose tissue may be an 17 effective approach to ameliorate obesity and associated metabolic diseases. 2 18 Introduction 19 Excess expansion of white adipose tissue (WAT) due to positive energy balance and/or defects in 20 thermogenesis in beige fat and brown adipose tissue (BAT) are associated with obesity and various 21 metabolic diseases such as inflammation, insulin resistance, and type 2 diabetes (1, 2). Adipose tissue 22 microenvironment (ATME), which is modulated by signaling pathway crosstalks between adipocytes 23 and neighboring cells such as resident or infiltrated macrophages, have a great impact on adipose tissue 24 function and systemic metabolic homeostasis (3, 4). However, the precise mechanisms by which 25 adipocytes crosstalk to macrophages in adipose tissue remain to be further elucidated. 26 FGF21, which is mainly produced in the liver and to a lesser extent in adipose tissue, muscle and 27 pancreas, has various metabolic beneficial effects such as reducing adiposity and hepatic triglyceride 28 content, promoting thermogenesis and energy expenditure, and improving insulin sensitivity (5). 29 Various studies have demonstrated that the physiological roles of FGF21 are mediated by its endocrine, 30 autocrine, and/or paracrine actions. FGF21 deficient mice exhibited decreased cold-induced thermogenic 31 gene expression in WAT but not BAT (6). It has also been found that adipose- but not liver-derived 32 FGF21 may regulate beige fat thermogenesis through a paracrine action (6, 7). However, how adipose 33 FGF21 is regulated to exerts its paracrine action and induce beige cell thermogenesis remains elusive. 34 MicroRNAs (miRNAs) are endogenous, noncoding small RNAs that post transcriptionally regulate 35 gene expression and have been shown to have important roles in numerous disease processes (8). In 36 adipose tissues, miRNAs play an important role in regulating the pathways that control a range of 37 processes including adipocyte differentiation, insulin signaling and glucose homeostasis (8). Recent 38 studies have demonstrated that some miRNA directly target and regulate thermogenic genes of brown 39 adipocyte development and the beiging of white adipocytes(9-11). Among adipose expressed miRNA, 40 miR-182-5p is highly enriched in differentiated brown adipocytes compared to non-differentiated cells 3 41 (12). However, whether and how miR-182-5p is involved in regulating beiging progress of WAT is 42 largely unknown. 43 In the current study, we show that adipose miR-182-5p levels are negatively associated with obesity 44 in mice and humans. Adipose miR-182-5p expression is induced by cold exposure in mice and its 45 deficiency suppresses cold-induced expression of genes involved in mitochondrial biogenesis and 46 thermogenesis. On the other hand, overexpression of miR-182-5p in adipose tissue promoted beiging of 47 white adipose tissue and thermogenesis, improved energy homeostasis and resisted diet-induced obesity. 48 By inhibiting Nr1d1, adipose miR-182-5p increases FGF21 expression and secretion, which in turn 49 stimulates the production and secretion of acetylcholine in macrophages. Acetylcholine potentiates 50 nAChR-mediated activation of the PKA signaling pathway in adipocytes and thus increased 51 thermogenic gene expression. Our study identifies a novel miR-182-5p/FGF21/acetylcholine/PKA 52 signaling circuit that mediates the crosstalk between adipocytes and adipose tissue-resident macrophages 53 to promote beige fat development and counteract overnutrition-induced obesity. Thus, up-regulation of 54 the miR-182-5p/FGF21/acetylcholine /PKA axis may be an effective approach to ameliorate obesity- 55 induced metabolic diseases. 56 57 58 Results 59 miR-182-5p expression in WAT is negatively correlated with obesity in mice and humans but is 60 stimulated by cold exposure in mice 61 To determine the potential role of miR-182-5p is beiging process, we exposed mice to cold. We 62 found that cold exposure greatly increased miR-182-5p levels in both sWAT (Figure 1A) and BAT 4 63 (Figure 1B) of mice. Interestingly, miR-182-5p had a much greater response to cold exposure in sWAT 64 (~100-fold changes) than in BAT (~3-fold changes), suggesting that miR-182-5p may have a major 65 function in regulating beige fat thermogenesis. miR-182-5p expression levels were significantly reduced 66 in sWAT of HFD-fed mice (Figure 1C) and ob/ob mice (Figure 1D) compared to their respective control 67 mice. The expression of miR-182-5p in sWAT was also negatively correlated with BMI in humans 68 (Figures 1E and 1F). These data suggest that miR-182-5p down-regulation may contribute to diet- 69 induced obesity. 70 miR-182-5p promotes beiging of white adipose tissue and energy expenditure in mice 71 Next, we investigated whether miR-182-5p deficiency affects cold-induced thermogenic gene 72 expression in mice. Because some of the homozygous miR-182-5p knockout mice were born with 73 defects such as shorter tails and lacking ears, which may complicate the interpretation of the data, we 74 used heterozygous miR-182-5p knockout mice (miR-182-5p+/-) in our study, which showed a significant 75 decrease in miR-182-5p levels in both sWAT (Figure S1A) and BAT (Figure S1B) compared to their 76 control mice but did not show any detectable growth, morphological, and metabolic defects under 77 normal housing condition. While miR-182-5p deficiency in mice had no effect on cold exposure- 78 induced Ucp1 gene expression in BAT (Figure S1C), it greatly suppressed cold-induced protein 79 expression of key regulators of beige fat thermogenesis such as UCP1, PGC1α, and CEBPβ in sWAT 80 (Figure 2A), as well as the formation of multilocular brown-like adipocytes (Figure 2B). Consistent with 81 these results, miR-182-5p+/- mice displayed a significant reduction in norepinephrine (NE)-induced 82 oxygen consumption (Figure 2C) and impaired cold tolerance at 4 ℃ (Figure S1D) compared to control 83 littermates. In addition, the miR-182-5p+/- mice gained more body weight on HFD at room temperature 84 (Figure S1E), probably due to impaired beige fat thermogenesis. Taken together, these results suggest 85 that miRNA-182-5p is an important regulator of energy expenditure. 5 86 To further determine the potential role of adipose miR-182-5p in regulating beige fat development 87 and thermogenesis in vivo, we established a fat pad injection technique using a modified procedure as 88 described (13, 14). Subcutaneous fat pad injection of miR-182-5p agomir, a synthetic double-stranded 89 miRNA that mimics endogenous miR-182-5p, significantly increased miR-182-5p level in sWAT 90 (Figure S1F) but not in BAT and eWAT (Figures S1G and S1H), demonstrating the specificity of the 91 injection.
Recommended publications
  • Dietary Supplementation with L-Arginine, Single Nucleotide
    The Journal of Nutrition Commentary Dietary Supplementation with L-Arginine, Single Nucleotide Polymorphisms of Arginase Downloaded from https://academic.oup.com/jn/advance-article/doi/10.1093/jn/nxaa431/6131937 by University of Memphis - Library user on 10 February 2021 1 and 2, and Plasma L-Arginine Keith R Martin Center for Nutraceutical and Dietary Supplement Research, College of Health Sciences, University of Memphis, Memphis, TN, USA There are ∼3 million single nucleotide polymorphisms (SNPs) Arginine-dependent NO impacts the immune, neuronal, and between 2 unrelated individuals, with each SNP representing cardiovascular systems and is a potent vasodilator critical for a single modification in the genomic code and cumulatively vascular tone, blood pressure modulation, vascular permeabil- representing 0.1% human genetic diversity. Although many of ity, and angiogenesis (7–9). SNPs in the ARG1 gene are clinically these differences are silent, relatively recent data suggest that associated with cardiovascular diseases such as hypertension, around half of the various responses to dietary agents could cardiomyopathy, myocardial infarction, and carotid intima be related to genetic variation, a field coined as nutrigenetics. media thickness, and upregulation of arginase is implicated in These variations are of considerable interest in improving the vascular dysfunction (10, 11). Thus, dietary supplementation health of individuals and collectively mitigating the risk of with l-arginine could be warranted. chronic disease. In this issue of the Journal, Hannemann et The study by Hannemann et al. is the first to describe al. (1) describe a possible functional relation between arginase an association between genotypes of ARG1 and ARG2 with isoforms, important in the urea cycle and nitric oxide (NO) consequent circulating plasma concentrations of l-arginine.
    [Show full text]
  • Mesenchymal Stem Cells Prevent the Progression of Diabetic
    Lee et al. Experimental & Molecular Medicine (2019) 51:77 https://doi.org/10.1038/s12276-019-0268-5 Experimental & Molecular Medicine ARTICLE Open Access Mesenchymal stem cells prevent the progression of diabetic nephropathy by improving mitochondrial function in tubular epithelial cells Seung Eun Lee1,2,7,JungEunJang1,2,8,HyunSikKim2,MinKyoJung2,MyoungSeokKo2,Mi-OkKim2, Hye Sun Park2, Wonil Oh3, Soo Jin Choi3,HyeJinJin3, Sang-Yeob Kim4,YunJaeKim2,SeongWhoKim5, Min Kyung Kim5, Chang Ohk Sung6, Chan-Gi Pack 2,Ki-UpLee1,2 and Eun Hee Koh1,2 Abstract The administration of mesenchymal stem cells (MSCs) was shown to attenuate overt as well as early diabetic nephropathy in rodents, but the underlying mechanism of this beneficial effect is largely unknown. Inflammation and mitochondrial dysfunction are major pathogenic factors in diabetic nephropathy. In this study, we found that the repeated administration of MSCs prevents albuminuria and injury to tubular epithelial cells (TECs), an important element in the progression of diabetic nephropathy, by improving mitochondrial function. The expression of M1 macrophage markers was significantly increased in diabetic kidneys compared with that in control kidneys. Interestingly, the expression of arginase-1 (Arg1), an important M2 macrophage marker, was reduced in diabetic kidneys and increased by MSC treatment. In cultured TECs, conditioned media from lipopolysaccharide-activated 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; macrophages reduced peroxisomal proliferator-activated receptor gamma coactivator 1α (Pgc1a) expression and impaired mitochondrial function. The coculture of macrophages with MSCs increased and decreased the expression of Arg1 and M1 markers, respectively. Treatment with conditioned media from cocultured macrophages prevented activated macrophage-induced mitochondrial dysfunction in TECs.
    [Show full text]
  • Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’S Biological Network Based on Systematic Pharmacology
    ORIGINAL RESEARCH published: 25 June 2021 doi: 10.3389/fphar.2021.601846 Exploring the Regulatory Mechanism of Hedysarum Multijugum Maxim.-Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’s Biological Network Based on Systematic Pharmacology Kailin Yang 1†, Liuting Zeng 1†, Anqi Ge 2†, Yi Chen 1†, Shanshan Wang 1†, Xiaofei Zhu 1,3† and Jinwen Ge 1,4* Edited by: 1 Takashi Sato, Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of 2 Tokyo University of Pharmacy and Life Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha, China, Galactophore Department, The First 3 Sciences, Japan Hospital of Hunan University of Chinese Medicine, Changsha, China, School of Graduate, Central South University, Changsha, China, 4Shaoyang University, Shaoyang, China Reviewed by: Hui Zhao, Capital Medical University, China Background: Clinical research found that Hedysarum Multijugum Maxim.-Chuanxiong Maria Luisa Del Moral, fi University of Jaén, Spain Rhizoma Compound (HCC) has de nite curative effect on cerebral ischemic diseases, *Correspondence: such as ischemic stroke and cerebral ischemia-reperfusion injury (CIR). However, its Jinwen Ge mechanism for treating cerebral ischemia is still not fully explained. [email protected] †These authors share first authorship Methods: The traditional Chinese medicine related database were utilized to obtain the components of HCC. The Pharmmapper were used to predict HCC’s potential targets. Specialty section: The CIR genes were obtained from Genecards and OMIM and the protein-protein This article was submitted to interaction (PPI) data of HCC’s targets and IS genes were obtained from String Ethnopharmacology, a section of the journal database.
    [Show full text]
  • Investigation of COVID-19 Comorbidities Reveals Genes and Pathways Coincident with the SARS-Cov-2 Viral Disease
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.306720; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Title: Investigation of COVID-19 comorbidities reveals genes and pathways coincident with the SARS-CoV-2 viral disease. Authors: Mary E. Dolan1*,2, David P. Hill1,2, Gaurab Mukherjee2, Monica S. McAndrews2, Elissa J. Chesler2, Judith A. Blake2 1 These authors contributed equally and should be considered co-first authors * Corresponding author [email protected] 2 The Jackson Laboratory, 600 Main St, Bar Harbor, ME 04609, USA Abstract: The emergence of the SARS-CoV-2 virus and subsequent COVID-19 pandemic initiated intense research into the mechanisms of action for this virus. It was quickly noted that COVID-19 presents more seriously in conjunction with other human disease conditions such as hypertension, diabetes, and lung diseases. We conducted a bioinformatics analysis of COVID-19 comorbidity-associated gene sets, identifying genes and pathways shared among the comorbidities, and evaluated current knowledge about these genes and pathways as related to current information about SARS-CoV-2 infection. We performed our analysis using GeneWeaver (GW), Reactome, and several biomedical ontologies to represent and compare common COVID- 19 comorbidities. Phenotypic analysis of shared genes revealed significant enrichment for immune system phenotypes and for cardiovascular-related phenotypes, which might point to alleles and phenotypes in mouse models that could be evaluated for clues to COVID-19 severity.
    [Show full text]
  • The Urea Cycle Is Transcriptionally Controlled by Hypoxia
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.25.428152; this version posted January 27, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The urea cycle is transcriptionally controlled by hypoxia-inducible factors Charandeep Singh1, Andrew Benos1, Allison Grenell1,2, Vincent Tran1, Demiana Hanna1, Bela Anand-Apte1,3, Henri Brunengraber4, Jonathan E. Sears1,5 1Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, OH 44195, USA. 2Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. 3Department of Ophthalmology and Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH 44195, USA. 4Department of Nutrition, Case Western Reserve School of Medicine Cleveland, Cleveland, OH, 44106, USA. 5Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, OH 44195, USA. Keywords Transcriptional regulation, stable-isotope, carbamoyl phosphate synthetase 1, arginase 1, FG-4592, urea cycle, HIF Abbreviations HIF PHi, hypoxia inducible factor-prolyl hydroxylase inhibition; OIR, oxygen induced retinopathy; CPS1, Carbamoyl phosphate synthetase I; ARG1, Arginase 1; ARG2, Arginase 2; OTC, Ornithine transcarbamylase; HNF3-β, Hepatocyte nuclear factors; bioRxiv preprint doi: https://doi.org/10.1101/2021.01.25.428152; this version posted January 27, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Here, we demonstrate transcriptional regulation of urea cycle genes CPS1 and ARG1 by hypoxia-inducible factors (HIFs) and demonstrate a hepatic HIF dependent increase in urea cycle activity.
    [Show full text]
  • (ARG1/1126) NBP2-47999-0.1Mg
    Product Datasheet Arginase 1/ARG1/liver Arginase Antibody (ARG1/1126) - Azide and BSA Free NBP2-47999-0.1mg Unit Size: 0.1 mg Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-47999 Updated 5/5/2021 v.20.1 Earn rewards for product reviews and publications. Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP2-47999 Page 1 of 3 v.20.1 Updated 5/5/2021 NBP2-47999-0.1mg Arginase 1/ARG1/liver Arginase Antibody (ARG1/1126) - Azide and BSA Free Product Information Unit Size 0.1 mg Concentration 1.0 mg/ml Storage Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. Clonality Monoclonal Clone ARG1/1126 Preservative No Preservative Isotype IgG3 Kappa Purity Protein A or G purified Buffer 10 mM PBS Target Molecular Weight 36.5 kDa Product Description Host Mouse Gene ID 383 Gene Symbol ARG1 Species Human Marker Hepatocellular Carcinoma Marker Specificity/Sensitivity Recognizes a protein of 35-38kDa, which is identified as Arginase 1 (ARG1). Arginase is a manganese metallo-enzyme that catalyzes the hydrolysis of arginine to generate ornithine and urea. Arginase I and II are isoenzymes, which differ in subcellular localization, regulation, and possibly function. Arginase I is a cytosolic enzyme, which is expressed mainly in the liver as part of the urea cycle, whereas arginase II is a mitochondrial protein found in a variety of tissues.
    [Show full text]
  • Molecular Docking Studies of Natural Compounds of Naringin on Enzymes Involved in the Urea Cycle Pathway in Hyperammonemia
    Arumugam et al Tropical Journal of Pharmaceutical Research May 2020; 19 (5): 1037-1043 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v19i5.19 Original Research Article Molecular docking studies of natural compounds of naringin on enzymes involved in the urea cycle pathway in hyperammonemia Ramakrishnan Arumugam1, Renuka Mani2, Amalan Venkatesan1, Senthilmurugan Sengamalai3, Vijayakumar Natesan1*, Sung-Jin Kim4* 1Department of Biochemistry and Biotechnology, Annamalai University, Tamilnadu, India, 2Department of Biotechnology, Periyar University, Tamilnadu, India, 3Department of Zoology, Annamalai University, Tamilnadu, India, 4Department of Pharmacology and Toxicology, Metabolic Diseases Research Laboratory, School of Dentistry, Kyung Hee University, Republic of Korea *For correspondence: Email: [email protected], [email protected]; Tel: +82-2-961-0868, +91-04144-239343 Sent for review: 18 September 2019 Revised accepted: 16 April 2020 Abstract Purpose: To investigate the anti-hyperammonemic activity of naringin by molecular docking via in silico studies. Methods: Urea cycle proteins were docked to the natural compound naringin as well as a standard drug, sodium benzoate. Hydrogen bonds and binding energy were obtained using Catalytic Site Atlas and Cast P Finder Software Tool. Results: There were six urea cycle enzymes, including N-acetyl glutamate synthase, carbamoyl phosphate synthase I, ornithine transcarbamylase, argininosuccinate synthase, argininosuccinate lyase and arginase I. On evaluating protein interactions with naringin, which is dynamically connected to the urea cycle pathway with hyperammonemia, naringin showed more hydrogen bonds and also produced higher binding energy when compared to the standard drug, sodium benzoate.
    [Show full text]
  • SUPPLEMENTARY MATERIAL Supplementary Fig. S1. LD Mice Used in This Study Accumulate Polyglucosan Inclusions (Lafora Bodies) in the Brain
    1 SUPPLEMENTARY MATERIAL Supplementary Fig. S1. LD mice used in this study accumulate polyglucosan inclusions (Lafora bodies) in the brain. Samples from the hippocampus of five months old control, Epm2a-/- (lacking laforin) and Epm2b-/- mice (lacking malin) were stained with periodic acid Schiff reagent (PAS staining), which colors polysaccharide granules in red. Bar: 50 m. Supplementary Fig. S2. Principal component analysis (PCA) representing the first two components with the biggest level of phenotypic variability. Samples 1_S1 to 4_S4 corresponded to control, 5_S5, 6_S6 and 8_S8 to Epm2a-/- and 9_S9 to 12_S12 to Epm2b- /- samples, of animals of 16 months of age respectively. Supplementary Table S1. Primers used in this work to validate the expression of the corresponding genes by RT-qPCR. Supplementary Table S2: Genes downregulated more than 0.5 fold in Epm2a-/- and Epm2b-/- mice of 16 months of age. The gene name, false discovery rate (FDR), fold change (FC), description and MGI Id (mouse genome informatics) are indicated. Genes are arranged according to FC. Supplementary Table S3: Genes upregulated more than 1.5 fold in Epm2a-/- mice of 16 months of age. The gene name, false discovery rate (FDR), fold change (FC), description and MGI Id (mouse genome informatics) are indicated. Genes are arranged according to FC. Supplementary Table S4: Genes upregulated more than 1.5 fold in Epm2b-/- mice of 16 months of age. The gene name, false discovery rate (FDR), fold change (FC), description and MGI Id (mouse genome informatics) are indicated. Genes are arranged according to FC. 2 Supplementary Table S5: Genes upregulated in both Epm2a-/- and Epm2b-/- mice of 16 months of age.
    [Show full text]
  • Arginase Isoforms Expression of Nitric Oxide Synthase and Populations Of
    Microenvironments in Tuberculous Granulomas Are Delineated by Distinct Populations of Macrophage Subsets and Expression of Nitric Oxide Synthase and This information is current as Arginase Isoforms of September 26, 2021. Joshua T. Mattila, Olabisi O. Ojo, Diane Kepka-Lenhart, Simeone Marino, Jin Hee Kim, Seok Yong Eum, Laura E. Via, Clifton E. Barry III, Edwin Klein, Denise E. Kirschner, Sidney M. Morris, Jr., Philana Ling Lin and JoAnne L. Downloaded from Flynn J Immunol 2013; 191:773-784; Prepublished online 7 June 2013; doi: 10.4049/jimmunol.1300113 http://www.jimmunol.org/content/191/2/773 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2013/06/07/jimmunol.130011 Material 3.DC1 References This article cites 66 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/191/2/773.full#ref-list-1 by guest on September 26, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • Arginase As a Potential Biomarker of Disease Progression: a Molecular Imaging Perspective
    International Journal of Molecular Sciences Review Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective Gonçalo S. Clemente 1 , Aren van Waarde 1, Inês F. Antunes 1, Alexander Dömling 2 and Philip H. Elsinga 1,* 1 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands; [email protected] (G.S.C.); [email protected] (A.v.W.); [email protected] (I.F.A.) 2 Department of Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +31-50-361-3247 Received: 2 July 2020; Accepted: 23 July 2020; Published: 25 July 2020 Abstract: Arginase is a widely known enzyme of the urea cycle that catalyzes the hydrolysis of L-arginine to L-ornithine and urea. The action of arginase goes beyond the boundaries of hepatic ureogenic function, being widespread through most tissues. Two arginase isoforms coexist, the type I (Arg1) predominantly expressed in the liver and the type II (Arg2) expressed throughout extrahepatic tissues. By producing L-ornithine while competing with nitric oxide synthase (NOS) for the same substrate (L-arginine), arginase can influence the endogenous levels of polyamines, proline, and NO•. Several pathophysiological processes may deregulate arginase/NOS balance, disturbing the homeostasis and functionality of the organism. Upregulated arginase expression is associated with several pathological processes that can range from cardiovascular, immune-mediated, and tumorigenic conditions to neurodegenerative disorders. Thus, arginase is a potential biomarker of disease progression and severity and has recently been the subject of research studies regarding the therapeutic efficacy of arginase inhibitors.
    [Show full text]
  • The Molecular Basis and Pathology of Phenotypic Variability in Urea Cycle Disorders
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2014 The Molecular Basis and Pathology of Phenotypic Variability in Urea Cycle Disorders Hu, Lyian Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-108004 Dissertation Published Version Originally published at: Hu, Lyian. The Molecular Basis and Pathology of Phenotypic Variability in Urea Cycle Disorders. 2014, University of Zurich, Faculty of Science. The Molecular Basis and Pathology of Phenotypic Variability in Urea Cycle Disorders Dissertation zur Erlangung der naturwissenschaftlichen Doktorwürde (Dr. sc. nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich von Liyan HU aus Taizhou, Zhejiang der V.R. China Promotionskomitee Prof. Dr. sc. nat. Beat W. Schäfer (Vorsitz) Prof. Dr. med. Johannes Häberle (Leitung der Dissertation) Prof. Dr. sc. nat. Thierry Hennet PD Dr. med. Jean-Marc Nuoffer Zürich, March 2014 The present study was performed from October 2010 till March 2014 in the metabolic laboratory at the Division of Metabolism, University Children’s Hospital Zürich under the supervision of Prof. Dr. med. Johannes Häberle. Publications represented in this study: 1. Understanding the Role of Argininosuccinate Lyase Transcript Variants in the Clinical and Biochemical Variability of the Urea Cycle Disorder Argininosuccinic Aciduria Liyan Hu, Amit V. Pandey, Sandra Eggimann, Véronique Rüfenacht, Dorothea Möslinger, Jean-Marc Nuoffer, Johannes Häberle (2013) The Journal of biological chemistry 288(48), 34599-34611 2. Variant forms of the urea cycle disorder argininosuccinic aciduria are caused by folding defects of argininosuccinate lyase Liyan Hu, Amit V.
    [Show full text]
  • Novel ARG1 Variants Identified in a Patient with Arginase 1 Deficiency
    Yokoi et al. Human Genome Variation (2021) 8:8 https://doi.org/10.1038/s41439-021-00139-9 Human Genome Variation DATA REPORT Open Access Novel ARG1 variants identified in a patient with arginase 1 deficiency Katsuyuki Yokoi 1,2, Yoko Nakajima1, Toshihiro Yasui3, Makoto Yoshino4,TetsushiYoshikawa1, Hiroki Kurahashi2 and Tetsuya Ito1 Abstract We report a case of a 13-year-old boy with arginase 1 deficiency carrying a new variant in ARG1. Sanger sequencing identified the compound heterozygous variants: NM_000045.4: c.365G>A (p.Trp122*)/c.820G>A (p.Asp274Asn). Although not previously reported, the p.Asp274Asn variant is predicted to have strong pathogenicity because it is located in a highly conserved domain in the protein core and arginase activity in the patient was below measurement sensitivity. Hyperargininemia is an extremely rare autosomal reces- NAGS (<1:2,000,000) and CPS1 (1:1,300,000) deficiencies4. sive condition that is associated with urea cycle disorder In Japan, the incidence of arginase 1 deficiency may be less (UCD); it is caused by a deficiency of arginase 1, which than that in the United States and Europe, i.e., an incidence hydrolyzes arginine to form ornithine and urea. ARG1,the of 1:2,200,000, per a previous report5. Here, we present a gene encoding arginase 1, is located on chromosome 6q23, case of 13-year-old boy with hyperargininemia. A novel 1 ARG1 fi 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; encompassing a 15-kb genomic region with 8 exons . variant was identi ed in this patient. Patients with arginase 1 deficiency show high levels of A 13-year-old boy with arginase 1 deficiency who was plasma arginine, relatively mild or moderate hyper- born to parents with no consanguinity was assessed.
    [Show full text]